Off-Label Rituximab Matches Ocrelizumab in MS

Medical professionals in India frequently search for cost-effective disease-modifying therapies for multiple sclerosis. Recently, the landmark Phase 3 OVERLORD-MS trial compared off-label rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. Consequently, this head-to-head study offers critical clinical clarity. The researchers evaluated MRI lesion activity over 24 months to assess comparative efficacy. Therefore, this trial holds major implications for resource-limited healthcare systems worldwide.

Key trial findings on rituximab versus ocrelizumab

In this double-blind, noninferiority trial, investigators randomly assigned 218 adults in a 3:2 ratio. Specifically, 132 patients received rituximab, while 84 received ocrelizumab. The primary endpoint measured the absence of new or enlarging T2 lesions on MRI scans. Surprisingly, the estimated probability of remaining lesion-free was 92.2% with rituximab and 94.8% with ocrelizumab. Thus, the risk difference was only -2.6 percentage points, meeting the strict noninferiority margin. Furthermore, relapse rates and disability progression remained virtually identical between both treatment cohorts.

Safety and Tolerability Comparison

While both drugs demonstrated impressive efficacy, safety outcomes revealed minor differences. To illustrate, infections occurred in 82% of the rituximab group compared to 69% of the ocrelizumab group. However, serious adverse events were nearly equivalent, occurring in 8% and 7% of participants, respectively. In addition, the long-term safety profiles of both anti-CD20 agents remained highly reassuring throughout the study. Therefore, clinicians can confidently select either agent based on patient-specific factors and medication access.

Clinical Implications for Physicians in India

In India, the high cost of newer disease-modifying therapies often limits patient access to optimal care. Consequently, many neurologists prescribe off-label rituximab as a pragmatic, highly effective first-line option. Since the OVERLORD-MS trial provides robust, randomized head-to-head evidence, it validates this common real-world practice. Moreover, using less expensive therapies can dramatically reduce the financial burden on families. Ultimately, these findings empower Indian healthcare providers to optimize outcomes without compromising patient safety or clinical success.

Frequently Asked Questions

Q1: Why is the comparison of rituximab and ocrelizumab significant?

Historically, robust head-to-head clinical trial data comparing these two B-cell depleting therapies were completely lacking. Consequently, this study provides the first high-level randomized evidence validating off-label rituximab as a highly effective, low-cost option.

Q2: Were there any major differences in safety between the two drugs?

Although serious adverse events were similar between both groups, infections occurred more frequently in patients receiving rituximab. Specifically, 82% of rituximab patients experienced infections, compared to 69% of ocrelizumab patients.

Q3: How do these trial findings impact clinical practice in resource-limited settings?

These findings suggest that clinicians can utilize lower-cost rituximab without compromising patient outcomes. Therefore, healthcare systems can expand access to early, highly effective MS treatments while preserving substantial financial resources.

References

1. Torkildsen Ø et al. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. N Engl J Med. 2026 Jul 02. doi: 10.1056/NEJMoa2600993. PMID: 42384870.
2. ClinicalTrials.gov. Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS). NCT04578639.
3. University of Bergen. Low-cost MS treatment shown to be as effective as standard therapy in landmark NEJM trial. Published July 2, 2026.